Net Deferred Revenues (Details Textual) (USD $) In Millions, unless otherwise specified	6 Months Ended
	Mar. 31, 2013	Nov. 30, 2002
Deferred Revenues (Additional Textual) [Abstract]
Sales price for undivided interest in the Company's rights to future Abreva royalties		$ 24.1
Annual net sales of Abreva threshold for royalty revenue	$ 62
Expiration of the patent for Abreva	Apr. 14, 2014
GSK License Agreement [Member]
Deferred Revenues (Textual) [Abstract]
Right to receive royalties	50.00%
Right to receive royalties ,net	4.00%